Literature DB >> 9166936

Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.

I H Borel Rinkes1, M R de Vries, A M Jonker, T J Swaak, C E Hack, P T Nooyen, T Wiggers, A M Eggermont.   

Abstract

Isolated limb perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan is well tolerated and highly effective in irresectable sarcoma and melanoma. No data are available on isolated hepatic perfusion (IHP) with these drugs for irresectable hepatic malignancies. This study was undertaken to assess the feasibility of such an approach by analysing hepatic and systemic toxicity of IHP with TNF-alpha with and without melphalan in pigs. Ten healthy pigs underwent IHP. After vascular isolation of the liver, inflow catheters were placed in the hepatic artery and portal vein, and an outflow catheter was placed in the inferior vena cava (IVC). An extracorporeal veno-venous bypass was used to shunt blood from the lower body and intestines to the heart. The liver was perfused for 60 min with (1) 50 microg kg(-1) TNF-alpha (n = 5), (2) 50 microg kg(-1) TNF-alpha plus 1 mg kg(-1) melphalan (n = 3) or (3) no drugs (n = 2). The liver was washed with macrodex before restoring vascular continuity. All but one pigs tolerated the procedure well. Stable perfusion was achieved in all animals with median perfusate TNF-alpha levels of 5.1 +/- 0.78 x 10(6) pg ml(-1) (+/- s.e.m). Systemic leakage of TNF-alpha from the perfusate was consistently < 0.02%. Following IHP, a transient elevation of systemic TNF-alpha levels was observed in groups 1 and 2 with a median peak level of 23 +/- 3 x 10(3) pg ml(-1) at 10 min after washout, which normalized within 6 h. No significant systemic toxicity was observed. Mild transient hepatotoxicity was seen to a similar extent in all animals, including controls. IHP with TNF-alpha with(out) melphalan in pigs is technically feasible, results in minimal systemic drug exposure and causes minor transient disturbances of liver biochemistry and histology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166936      PMCID: PMC2223506          DOI: 10.1038/bjc.1997.248

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  47 in total

1.  In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue.

Authors:  L M de Brauw; C J van de Velde; U R Tjaden; E A de Bruijn; A V Bell; J Hermans; A Zwaveling
Journal:  J Surg Res       Date:  1988-02       Impact factor: 2.192

2.  A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases.

Authors:  A E Chang; P D Schneider; P H Sugarbaker; C Simpson; M Culnane; S M Steinberg
Journal:  Ann Surg       Date:  1987-12       Impact factor: 12.969

Review 3.  The case for high-dose chemotherapy: is it chemotherapy's last gamble?

Authors:  G P Canellos
Journal:  Eur J Cancer Clin Oncol       Date:  1987-04

4.  Toxic effect of tumor necrosis factor on tumor vasculature in mice.

Authors:  N Watanabe; Y Niitsu; H Umeno; H Kuriyama; H Neda; N Yamauchi; M Maeda; I Urushizaki
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

5.  A technique for isolated liver perfusion in the rat with survival and results of cytotoxic drug perfusion on liver tumor growth.

Authors:  M Radnell; B Jeppsson; S Bengmark
Journal:  J Surg Res       Date:  1990-11       Impact factor: 2.192

6.  Vascularization of small liver metastases.

Authors:  S G Archer; B N Gray
Journal:  Br J Surg       Date:  1989-06       Impact factor: 6.939

7.  Portal infusion of tumor necrosis factor increases mortality in rats.

Authors:  M P Kahky; C O Daniel; A B Cruz; H V Gaskill
Journal:  J Surg Res       Date:  1990-08       Impact factor: 2.192

8.  A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.

Authors:  B Feinberg; R Kurzrock; M Talpaz; M Blick; S Saks; J U Gutterman
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

9.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

10.  Kinetics and parameters of the induction of interleukin 1 secretion by rat Kupffer cells.

Authors:  M Shirahama; H Ishibashi; Y Tsuchiya; S Kurokawa; Y Okumura; Y Niho
Journal:  J Clin Lab Immunol       Date:  1988-11
View more
  6 in total

1.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.

Authors:  M G van Ijken; E A de Bruijn; G de Boeck; T L ten Hagen; J R van der Sijp; A M Eggermont
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

2.  True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Carlo Ori; Federico Innocente; Romano Scalerta; Mauro Ceccherini; Pier Paolo Da Pian; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

3.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.

Authors:  J H de Wilt; E R Manusama; S T van Tiel; M G van Ijken; T L ten Hagen; A M Eggermont
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

4.  Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.

Authors:  A L Vahrmeijer; J H van Dierendonck; H J Keizer; J H Beijnen; R A Tollenaar; M E Pijl; A Marinelli; P J Kuppen; J H van Bockel; G J Mulder; C J van de Velde
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

5.  In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.

Authors:  A H van der Veen; A L Seynhaeve; J Breurs; P T Nooijen; R L Marquet; A M Eggermont
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

6.  Evaluation of Delcath Systems' Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion.

Authors:  Fred M Moeslein; Elizabeth G McAndrew; William M Appling; Nicole E Hryniewich; Kevin D Jarvis; Steven M Markos; Timothy P Sheets; Rajneesh P Uzgare; Daniel S Johnston
Journal:  Cardiovasc Intervent Radiol       Date:  2014-01-09       Impact factor: 2.740

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.